Data on Chimerix, Inc.'s CMX001 Selected for Two Oral Presentations at the 26th International Conference on Antiviral Research
5/10/2013 9:17:57 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DURHAM, N.C., May 10, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum antiviral compound CMX001 at the International Society for Antiviral Research's 26th International Conference on Antiviral Research (ICAR). ICAR is being held May 11-15, 2013 at the Hyatt Regency in San Francisco, CA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by